Clinical Trial Update: A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for GNC-038, a tetra-specific antibody, in primary central nervous system lymphoma and relapsed or refractory secondary CNS lymphoma, cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• GNC-038

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING